The research was in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine. This study adds to the previous studies of p...
OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in...
Under normal circumstances, interactions between PD-1 and its ligand PD-L1 can halt or limit the immune system’s response to human cells and suppress...
Cancer is one of the leading causes of death across Asian countries. According to a report published by Janssen Asia Pacific, in 2017, overall, there wer...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
he Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023- Everest Medicines (HKEX 1952.HK, "...
The oversubscribed financing was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Canc...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) announced the U.S. Food and Drug Administrati...
PHC is a subsidiary of PHC Group*1, a global healthcare company that develops, manufactures, sells, and services solutions across the business domains of d...
JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, announced involvement with two new research breakthroughs that demonstrate expande...
No patient with cancer should be denied care because of social determinants. The equity gap in cancer is costing lives. If we unite and work to...
The gold standard clinical assessment of treatment response is to measure changes in tumor volume over time. Typically, the RECIST (Response Evaluation Cri...
© 2024 Biopharma Boardroom. All Rights Reserved.
